Archive for the ‘Publications’ Category
-
Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22November 22nd, 2011To purchase a PDF copy of this article please click here.
-
The fibrosis marker galectin-3 and outcome in the general population: data from PREVEND
October 25th, 2011To purchase a PDF copy of this article please click here.
-
Galectin-3 in heart failure: high levels are associated with all-cause mortality
August 4th, 2011To purchase a PDF copy of this article please click here.
-
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction – de Boer RA, et al
January 3rd, 2011[Abstract] Aims. Galectin-3 is an emerging biomarker which has been studied in relatively small heart failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base-line galectin-3 in a large HF cohort, with preserved and reduced left ventricular ejection fraction (LVEF), and compared this to other biomarkers.
To download a complete, licensed PDF of this article from the publisher, click here.
-
Galectin-3 in Heart Failure–Linking Fibrosis, Remodeling, and Progression – deFilippi CR, Felker GM
- Comments Off
- Post a Comment
[Abstract] For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others, there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodeling that represents an intriguing link between inflammation and fibrosis. In this article, we review the biology of galectin-3, recent clinical research, and its application in the management of heart failure patients. To request a full-text, licensed “e-book” version of this article, complete the form below. All fields are required.
-
Clinical Validation of a Novel Assay for Galectin-3 for Risk Assessment in Acutely Destabilized Heart Failure
- Comments Off
- Post a Comment
Presentation of an oral abstract originally presented on September 15, 2009 at the 13th Annual Scientific Meeting of the Heart Failure Society of America, Boston, MA.
Complete the form below to request a copy of this PowerPoint presentation in PDF format.
-
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study – Lok DJA, et al.
- Comments Off
- Post a Comment
The prognostic value of galectin-3 was evaluated in 232 patients with chronic heart failure (HF) (NYHA Class III and IV) who were followed for 6.5 years. The mean age was 71 ± 10 years, 72% were male, and most (96%) were in NYHA Class III. Galectin-3 was a significant predictor of mortality risk, after adjustment for age, sex, severity of HF (assessed by NT-proBNP), and renal function (eGFR) – hazard ratio per standard deviation 1.24; 95% CI 1.03-1.50; P=0.026). The authors conclude that galectin-3 is a novel prognostic marker in chronic HF, its prognostic value is independent of severity of HF (assessed by NT-proBNP), and it may potentially be useful in the management of such patients.
Loading ...